The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
Adults with abdominal obesity are at high risk for cardiovascular disease and also exhibit
diminished growth hormone (GH) secretion; the latter further contributes to the development
of visceral adiposity, impaired fibrinolysis and inflammation.Growth hormone releasing
hormone (GHRH), the primary stimulus for endogenous GH secretion, is a substrate of
dipeptidyl peptidase 4 (DPP4); inhibition of DPP4 with the currently available anti-diabetic
therapy, sitagliptin, may therefore increase GH secretion by decreasing the degradation of
GHRH. The proposed research will test the hypothesis that chronic sitagliptin therapy will
enhance GH secretion and vascular function while improving glucose tolerance in patients with
impaired GH secretion who are at risk for the development of diabetes mellitus and
cardiovascular disease, specifically obese women with polycystic ovary syndrome.